Sitryx Therapeutics Secures $39 Million to Advance Immunometabolism-Targeted Therapies for Autoimmune and Inflammatory Diseases
Sitryx
Developer of Immuno-Oncology and Immuno-Inflammation Therapies
Oxford Science Enterprises
Science Construction Service Provider
SV Health Investors
Healthcare and Life Sciences Venture Capital Firms
Eli Lilly
Global Pharmaceutical R&D and Production Company
Sofinnova Partners
Venture Capital Firms
Longwood Fund
Fund Management Agency
GSK
Pharmaceutical R&D Manufacturer
September 27,Oxford, UK - Sitryx Therapeutics, a biopharmaceutical company focused on modulating cellular metabolism to develop disease-modifying therapies for chronic autoimmune and inflammatory diseases, announces successful completion$39 million (£32 million) New Round of Financing，SitryxPreviously, in October 2018, a $30 million Series A round was completed. New investor Oxford Science Enterprises (OSE) joined existing investors SV Health Investors, Eli Lilly and Company, Sofinova Partners, Longwood Fund, and GlaxoSmithKline. The total funding to date exceeds $75 million.
In 2020, Sitryx established a global licensing and research collaboration with Eli Lilly and Company.
Sitryx was founded in 2018 by world-leading researchers in the fields of immunology and metabolism, including Houman Ashrafian, Luke O'Neill, Jonathan Powell, Jeff Rathmell, Michael Rosenblum, and Paul Peter Tak. Together, they have published over 1,000 papers in the field, achieving several key breakthroughs in understanding how the energy states of immune cells play a critical role in regulating disease activity.
Sitryx to Use Proceeds to Advance Immuno-Metabolism Targeted Therapies into Clinical Development. The company is building a broad and differentiated proprietary pipeline of therapies by identifying novel targeting approaches based on how metabolic changes regulate immune cell function.
